• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. Journal of Pharmacology and Toxicology
  2. Vol 2 (3), 2007
  3. 205-219
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

Journal of Pharmacology and Toxicology

Year: 2007 | Volume: 2 | Issue: 3 | Page No.: 205-219
DOI: 10.3923/jpt.2007.205.219

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 528

Search


Authors


Pitchai Balakumar

Country: India

Madhankumar Rose

Country: India

Manjeet Singh

Country: India

Keywords


  • PPAR family
  • cardiovascular complications
  • PPAR agonists
Research Article

Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications

Pitchai Balakumar, Madhankumar Rose and Manjeet Singh
Peroxisome Proliferator Activated Receptors (PPARs) are ligand-activated transcription factors of nuclear hormone receptor superfamily. The PPAR subfamily comprises of three members such as PPARα, PPARγ and PPARδ. Activation of PPARα induces gene expressions that promote fatty acid oxidation. Fibrates, which are currently used as hypolipidemic agents are PPARα ligands. PPARγ regulates gene expressions that promote insulin sensitization followed by glucose metabolism. Thiazolidinediones, which are presently employed as insulin-sensitizing anti-diabetic agents are PPARγ agonists. On the other hand, PPARδ also known as PPARβ is expressed ubiquitously and involved in fatty acid oxidation in tissues, which lack PPARα. But no selective PPARδ agonists are currently available for therapeutic use. Evidences from ongoing pre-clinical and clinical studies suggest that PPAR ligands exert broad spectrum of cardioprotective activities in addition to their above-mentioned properties. Agonists of PPARs are shown to inhibit the pathogenesis of atherosclerosis, endothelial dysfunction, heart failure and myocardial infarction. In this review, we discussed various recently developed PPAR ligands and their potential role in the prevention of pathogenesis of cardiovascular complications. Moreover, the novel class of currently developed PPAR dual agonists such as PPARα/γ and PPARα/δ agonists and pan agonists such as PPARα/γ/δ agonists have also been discussed, which may be novel emerging therapeutic agents for cardiovascular complications.
PDF Fulltext XML References Citation

How to cite this article

Pitchai Balakumar, Madhankumar Rose and Manjeet Singh, 2007. Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications. Journal of Pharmacology and Toxicology, 2: 205-219.

DOI: 10.3923/jpt.2007.205.219

URL: https://scialert.net/abstract/?doi=jpt.2007.205.219

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved